Adenomyosis and Ulipristal Acetate

Inclusion Criteria: * Not postmenopausal women aged 30 to 50, * Accepting to give consent informed in writing, * Suffering from a symptomatic pelvic endometriosis (menorrhagia isolated or associated with pain) * Diagnosis information, confirmed the adenomyosis (T2-weighted) MRI and/or transvaginal ultrasonography, in the 6 months preceding the inclusion-having a score of bleeding (PBAC) \> 100 from J1 to J8 of the menstruation before the visit of inclusion, * With an index of body mass (IMC) ≥18 and \< 40, * Using a reliable method of non-hormonal contraception (non-hormonal intrauterine device (IUDs), sexual abstinence, diaphragm, condoms or vasectomy by the partner, or having undergone a surgical sterilization), * Willing and able to complete auto-questionnaires in french * Had no difficulties to understand and communicate with the investigator and his representatives * Affiliation to a social security or assign. Exclusion Criteria: * Patient with a hormonal oral contraceptive or with a hormonal intrauterine Device (IUD) contraceptive * Patient with a history of surgery (other than a caesarean or a cervical conization) uterus, ablation endometrial or uterine artery embolization, * With other than the endometriosis endometrial pathology, * Suffering of myoma of type 0, 1, 2 or 3, * Requiring a transfusion or having a ≤6g/dL hemoglobin * Existence of systemic coagulation, * History of thromboembolism * Progestagen taking severe disorders in the month preceding the tour selection, and corticosteroids and aspirin in the previous week, * Existence of Pathology renal, respiratory or cardiac severe or progressive, * Having a disturbed liver function (defined by the aspartate aminotransferase (ASAT), Alanine Amino Transferase (ALAT), γGlutamylTranspeptidase, alkaline phosphatase or total bilirubin above 2 times the upper limit of normal), * Existence or suspicion of malignancy, * Considering pregnancy in the coming year, * Pregnant patient or nursing * Any clinical condition that the investigator considers incompatible with the conduct of the study in terms of acceptable security, * Participation in courses at another clinical study * Patient whose accession to the test procedures may be insufficient or for which a long term follow-up seems difficult to achieve * Person under authorship or curators under safeguard of justice * History of hypersensitivity to the ulipristal or any of the excipients of ESMYA ® 5 mg tablet.